Literature DB >> 34290356

3D tumor spheroid microarray for high-throughput, high-content natural killer cell-mediated cytotoxicity.

Sneha Gopal1, Seok-Joon Kwon2, Bosung Ku3, Dong Woo Lee4, Jungeun Kim3, Jonathan S Dordick5,6.   

Abstract

Immunotherapy has emerged as a promising approach to treating several forms of cancer. Use of immune cells, such as natural killer (NK) cells, along with small molecule drugs and antibodies through antibody dependent cell-mediated cytotoxicity (ADCC) has been investigated as a potential combination therapy for some difficult to treat solid tumors. Nevertheless, there remains a need to develop tools that support co-culture of target cancer cells and effector immune cells in a contextually relevant three-dimensional (3D) environment to provide a rapid means to screen for and optimize ADCC-drug combinations. To that end, here we have developed a high throughput 330 micropillar-microwell sandwich platform that enables 3D co-culture of NK92-CD16 cells with pancreatic (MiaPaCa-2) and breast cancer cell lines (MCF-7 and MDA-MB-231). The platform successfully mimicked hypoxic conditions found in a tumor microenvironment and was used to demonstrate NK-cell mediated cell cytotoxicity in combination with two monoclonal antibodies; Trastuzumab and Atezolizumab. The platform was also used to show dose response behavior of target cancer cells with reduced EC50 values for paclitaxel (an anti-cancer chemotherapeutic) when treated with both NK cells and antibody. Such a platform may be used to develop more personalized cancer therapies using patient-derived cancer cells.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 34290356     DOI: 10.1038/s42003-021-02417-2

Source DB:  PubMed          Journal:  Commun Biol        ISSN: 2399-3642


  59 in total

Review 1.  Delivery technologies for cancer immunotherapy.

Authors:  Rachel S Riley; Carl H June; Robert Langer; Michael J Mitchell
Journal:  Nat Rev Drug Discov       Date:  2019-03       Impact factor: 84.694

2.  Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Authors:  Sattva S Neelapu; Frederick L Locke; Nancy L Bartlett; Lazaros J Lekakis; David B Miklos; Caron A Jacobson; Ira Braunschweig; Olalekan O Oluwole; Tanya Siddiqi; Yi Lin; John M Timmerman; Patrick J Stiff; Jonathan W Friedberg; Ian W Flinn; Andre Goy; Brian T Hill; Mitchell R Smith; Abhinav Deol; Umar Farooq; Peter McSweeney; Javier Munoz; Irit Avivi; Januario E Castro; Jason R Westin; Julio C Chavez; Armin Ghobadi; Krishna V Komanduri; Ronald Levy; Eric D Jacobsen; Thomas E Witzig; Patrick Reagan; Adrian Bot; John Rossi; Lynn Navale; Yizhou Jiang; Jeff Aycock; Meg Elias; David Chang; Jeff Wiezorek; William Y Go
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

Review 3.  Immunotherapy and targeted therapy combinations in metastatic breast cancer.

Authors:  Francisco J Esteva; Vanessa M Hubbard-Lucey; Jun Tang; Lajos Pusztai
Journal:  Lancet Oncol       Date:  2019-03       Impact factor: 41.316

Review 4.  Evolving synergistic combinations of targeted immunotherapies to combat cancer.

Authors:  Ignacio Melero; David M Berman; M Angela Aznar; Alan J Korman; José Luis Pérez Gracia; John Haanen
Journal:  Nat Rev Cancer       Date:  2015-08       Impact factor: 60.716

Review 5.  Personalized peptide vaccines and their relation to other therapies in urological cancer.

Authors:  Takahiro Kimura; Shin Egawa; Hirotsugu Uemura
Journal:  Nat Rev Urol       Date:  2017-05-31       Impact factor: 14.432

6.  Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors.

Authors:  Daniel W Beury; Katherine H Parker; Maeva Nyandjo; Pratima Sinha; Kayla A Carter; Suzanne Ostrand-Rosenberg
Journal:  J Leukoc Biol       Date:  2014-08-28       Impact factor: 4.962

Review 7.  Small molecules, big impact: 20 years of targeted therapy in oncology.

Authors:  Philippe L Bedard; David M Hyman; Matthew S Davids; Lillian L Siu
Journal:  Lancet       Date:  2020-03-28       Impact factor: 79.321

Review 8.  Challenges and Opportunities for Pancreatic Cancer Immunotherapy.

Authors:  Adham S Bear; Robert H Vonderheide; Mark H O'Hara
Journal:  Cancer Cell       Date:  2020-09-17       Impact factor: 31.743

Review 9.  Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics.

Authors:  Anabel Sorolla; Edina Wang; Emily Golden; Ciara Duffy; Sónia T Henriques; Andrew D Redfern; Pilar Blancafort
Journal:  Oncogene       Date:  2019-10-21       Impact factor: 9.867

10.  CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.

Authors:  Yu Zhu; Brett L Knolhoff; Melissa A Meyer; Timothy M Nywening; Brian L West; Jingqin Luo; Andrea Wang-Gillam; S Peter Goedegebuure; David C Linehan; David G DeNardo
Journal:  Cancer Res       Date:  2014-07-31       Impact factor: 12.701

View more
  6 in total

Review 1.  In Vitro Human Cancer Models for Biomedical Applications.

Authors:  Jane Ru Choi; Gül Kozalak; Ighli di Bari; Quratulain Babar; Zahra Niknam; Yousef Rasmi; Kar Wey Yong
Journal:  Cancers (Basel)       Date:  2022-05-03       Impact factor: 6.575

2.  Editorial: Recent 3D Tumor Models for Testing Immune-Mediated Therapies.

Authors:  Jacques Zimmer; Roberta Castriconi; Silvia Scaglione
Journal:  Front Immunol       Date:  2021-11-18       Impact factor: 7.561

Review 3.  Going with the Flow: Modeling the Tumor Microenvironment Using Microfluidic Technology.

Authors:  Hongyan Xie; Jackson W Appelt; Russell W Jenkins
Journal:  Cancers (Basel)       Date:  2021-12-01       Impact factor: 6.575

4.  A three-dimensional immune-oncology model for studying in vitro primary human NK cell cytotoxic activity.

Authors:  Nontaphat Thongsin; Methichit Wattanapanitch
Journal:  PLoS One       Date:  2022-03-21       Impact factor: 3.240

5.  Miniaturized and multiplexed high-content screening of drug and immune sensitivity in a multichambered microwell chip.

Authors:  Niklas Sandström; Valentina Carannante; Karl Olofsson; Patrick A Sandoz; Elisabeth L Moussaud-Lamodière; Brinton Seashore-Ludlow; Hanna Van Ooijen; Quentin Verron; Thomas Frisk; Madoka Takai; Martin Wiklund; Päivi Östling; Björn Önfelt
Journal:  Cell Rep Methods       Date:  2022-07-18

6.  A multi-organ-on-chip to recapitulate the infiltration and the cytotoxic activity of circulating NK cells in 3D matrix-based tumor model.

Authors:  Monica Marzagalli; Giorgia Pelizzoni; Arianna Fedi; Chiara Vitale; Fabrizio Fontana; Silvia Bruno; Alessandro Poggi; Alessandra Dondero; Maurizio Aiello; Roberta Castriconi; Cristina Bottino; Silvia Scaglione
Journal:  Front Bioeng Biotechnol       Date:  2022-07-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.